Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.52 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.49 |
| ▸ | ACACB | O00763 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27502717 | 1.00 | TACR1 (0.52) | TACR1NLRP3ACACBKMT2APKM | |
| SCHEMBL259952 | 0.89 | NLRP3 (0.59) | TACR1NLRP3ACACBALDH1A1FDPS | |
| SCHEMBL17053683 | 0.89 | NLRP3 (0.59) | TACR1NLRP3ACACBALDH1A1FDPS | |
| SCHEMBL6739005 | 0.86 | NLRP3 (0.49) | NLRP3KMT2APKMTP53CYP3A4 | |
| SCHEMBL3781118 | 0.83 | GPR132 (0.55) | ACACBFDPSGPR132 | |
| SCHEMBL6806623 | 0.83 | TACR1 (0.53) | TACR1NLRP3ACACBTP53POLB | |
| SCHEMBL30801050 | 0.83 | GPR132 (0.55) | ACACBFDPSGPR132 | |
| SCHEMBL6192282 | 0.83 | GPR132 (0.55) | ACACBFDPSGPR132 | |
| SCHEMBL3781113 | 0.83 | GPR132 (0.55) | ACACBFDPSGPR132 | |
| SCHEMBL242241 | 0.83 | TACR1 (0.71) | TACR1TP53ALDH1A1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1202096-C | 2-aminothiazoline derivatives and their use as no-synthase inhibitors | AVENTIS PHARMA SA (FR) | 2005-05-18 | — | — | CN | disclosed |
| US-6699895-B2 | CYCLIZING THE TERT-BUTYL-THIOUREA DERIVATIVE TO FORM THE END PRODUCT | AVENTIS PHARMA S.A. (FR) | 2004-03-02 | — | — | US | disclosed |
| CN-1444572-A | 2-aminothiazoline derivatives and their use as no-synthase inhibitors | AVENTIS PHARMA SA (FR) | 2003-09-24 | — | — | CN | disclosed |
| US-20020198243-A1 | 2-aminothiazoline derivatives and process for preparing the same | CARRY JEAN-CHRISTOPHE (FR) | 2002-12-26 | — | — | US | disclosed |
| US-20020187987-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible NO-synthase | CARRY JEAN-CHRISTOPHE (FR) | 2002-12-12 | — | — | US | disclosed |
| US-6451821-B1 | ADMINISTERING TO A PATIENT A THERAPEUTICALLY EFFECTIVE AMOUNT OF 2-AMINOTHIAZOLINE DERIVATIVES FOR TREATING OR PREVENTING DISEASE CONDITIONS ASSOCIATED WITH AN ABNORMAL PRODUCTION OF NITRIC OXIDE(NO) | AVENTIS PHARMA S.A. (FR) | 2002-09-17 | — | — | US | disclosed |
| US-20020022631-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase | AVENTIS PHARMA S.A. (FR) | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022631-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase | NOS2, NOS3, NOS1 | TACR1 1250/4885NLRP3 2047/4885ACACB 536/4885 |
| US-20020198243-A1 | 2-aminothiazoline derivatives and process for preparing the same | NOS3, TH, CBR1 | TACR1 1044/4885NLRP3 1499/4885ACACB 952/4885 |
| US-20020187987-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible NO-synthase | NOS2, NOS3, NOS1 | TACR1 1241/4885NLRP3 2212/4885ACACB 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.